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SUMMARY
BACKGROUND: Atypical teratoid rhabdoid tumours (ATRT) are very rare children’s cancers. Approxi-
mately 200 cases of ATRT located in the central nervous system have been described in the literature 
up till now.
AIM: The aim of this report was to analyze the results of treatment of 8 children with these very rare 
neoplasms of the central nervous system, who were treated according to the Polish Paediatric Brain 
Tumour Group protocol.
MATERIAL AND METHODS: Eight children aged from 4 months to 22 years, 5 girls, 3 boys with ATRT of 
the central nervous system are presented. All children have been operated on and received multidrug 
chemotherapy; 5 children received radiotherapy as well. In all craniospinal irradiation was applied, in 
doses of 35 Gy to the whole axis and 55 Gy to tumour boost.
RESULTS: Five patients died and 3 children are still alive. The progression-free survival of all 8 patients 
was 3 to 73 months. The overall survival was 5 to 73 months. All living children received radiotherapy. 
Two of them had total surgical resection and one partial.
CONCLUSIONS: We conclude that radiotherapy prolonged survival in ATRT and should be incorporated 
in all treatment protocols for patients with this diagnosis.
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BACKGROUND
Atypical teratoid rhabdoid tumours (ATRT) 
are very rare children’s cancers. They were 
described by Beckwith in 1978 as malignant 
rhabdoid tumours located in the kidney [1]. 
Cerebral location was acknowledged in the 
late 1980s. To date, approximately 200 cases 
of atypical teratoid/rhabdoid tumours of the 
central nervous system have been described in 
the literature [2]. Although ATRT accounts for 
less than 5% of all paediatric CNS tumours, up 
to 20% of malignant brain tumours diagnosed 
in patients less than 3 years old are ATRTs. 
In adults this tumour was reported anecdot-
ally [3,4]. The cerebral form of ATRT has been 
mistaken for PNET/medulloblastoma tumours. 
There are many publications about diagnostic 
diffi culties, especially for pathologists, when 
differentiating between PNET/medulloblas-
toma and ATRT [5, 6, 7]. These tumours have 
also been mistaken for ependymomas. Despite 
immunohistochemical and genetic testing it 
is very diffi cult to fi nd differences between 
ATRT and PNET, especially in infratentorial 
location [8, 9, 10, 11, 12, 13]. This distinction is 
important, because survival times in ATRT are 
much shorter than those obtained for medullo-
blastoma/PNETs, and a signifi cant portion of 
patients die as a result of local or craniospinal 
recurrence despite aggressive surgery and che-
motherapy. There are no treatment standards 
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for ATRT because of their rarity, but there is 
some evidence that long-term survival can oc-
cur with the use of adjuvant radiation therapy 
[2, 14, 15].
AIM
The aim of our study is to present clinical sta-
tus and treatment approaches in 8 patients 
with ATRT, treated according to the Polish 
Paediatric Brain Tumours Group protocol.
MATERIALS AND METHODS
Between 2000 and 2008, 8 children with ATRT 
aged from 4 months to 22 years were treated 
according to the Polish Paediatric Brain Tu-
mours Group protocol [16, 17]. There were 5 
girls and 3 boys. In 8 patients fi nal histopatho-
logical diagnosis of ATRT was confi rmed. 
Diagnostic diffi culties concerning histo-
pathology were confi rmed in 3 patients. In 2 
children the tumour samples had histological 
features similar to PNET. However, results 
were uncertain and further examinations 
of the tumour tissue were performed, which 
fi nally confi rmed ATRT. One child had a tu-
mour with a pathological tissue image typi-
cal for medulloblastoma. He was reoperated 
again because of disease progression during 
chemotherapy. The tissue specimen obtained 
during the surgery was typical for ATRT. In 
these patients immunohistochemical data for 
INI-1 were not obtained.
In 2 children tumours were located in the 
posterior fossa region and 6 patients had su-
pratentorial location. All children received 
radical treatment including surgery: 3 patients 
underwent total surgery, 3 subtotal and 2 par-
tial resection. Multidrug chemotherapy was 
introduced as part of their treatment for all 
8 patients. Three children received multidrug 
chemotherapy according to the Polish proto-
col for children below 3 years old (vincristine, 
etoposide, cisplatin, cyclophosphamide). In 5 
patients chemotherapy was given according to 
the standard Polish protocol for medulloblas-
toma/PNET (vincristine, etoposide, carbopla-
tin, ifosfamide, cisplatin).
Five children received radiotherapy; in all 
craniospinal irradiation was applied, in doses 
of 35 Gy to the whole axis and 55 Gy to tumour 
boost. This method was similar to that applied 
to medulloblastoma patients [18].
Three patients did not receive radiotherapy 
at all. In two cases progression during chemo-
therapy was observed, and one child was too 
young for radiotherapy.
RESULTS
Five patients died and three are still alive, 
with no evidence of disease. There are two 
girls and one boy in the group of living chil-
dren. One of them is suffering due to second 
cancer (myeloblastic leukaemia). Four deaths 
were caused by local progression, and one pa-
tient died because of local progression accom-
panied by massive dissemination to the brain 
and spinal cord. This patient passed away 
before planned radiotherapy. The overall sur-
vival of all 8 patients was 5 to 73 months. The 
progression-free survival of all 8 patients was 
3 to 73 months. All living patients received 
radiotherapy as part of their treatment. Two 
of them had total resection of the tumour and 
one partial. Treatment results are presented 
in table 1.
DISCUSSION
ATRT of the cerebral region are among tu-
mours with the worst prognosis. Despite 
worldwide multiple research concerning these 
types of tumours, obtained treatment results 
are still poor. Diagnostic and therapeutic dif-
fi culties are related to the rarity of these tu-
mours. Hence, the possibility of randomized 
multicentre trials assessing treatment effi -
ciency is limited. So far, genetic and immuno-
histochemical research in the fi eld of ATRT 
have not resulted in any signifi cant progress 
in therapeutic and diagnostic procedures in-
cluding differentiation between ATRT and 
PNET/medulloblastoma. 
There are publications describing long-arm 
deletion of chromosome 22q and gene INI1 
mutation [9, 12, 19, 20]. From the immunohis-
tochemical point of view the following staining 
methods seem to be signifi cant when differen-
tiating ATRT from PNET: E-cadherin, N-cad-
herin, beta-catenin immunoreactions [21]. In 
Rorke’s report diagnostic diffi culties with dis-
tinction between ATRT and PNET/medulloblas-
toma did not improve treatment results. 13% of 
ATRT were composed purely of rhabdoid cells, 
31% of ATRT had malignant mesenchymal com-
ponents, 67% were PNET/ATRT [22].
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Numerous publications inform about mis-
diagnosed tumours, especially in the in-
fratentorial location, where they resemble 
medulloblastoma tumours and are frequently 
mistaken for them [3, 5, 6, 7, 8, 11, 12]. Accord-
ing to the Koral report on preoperative MRI 
examinations of 36 patients with medulloblas-
toma and 19 with ATRT, conventional MRI 
showed similar characteristics between ATRT 
and medulloblastoma. Cerebellopontine angle 
involvement and intratumoural haemorrhage 
are more common in atypical teratoid rhab-
doid tumour [23]. In our patients, diagnostic 
diffi culties were noted in two cases. One pa-
tient (a boy, 4 months old) had a tumour with 
location and histology typical for medulloblas-
toma. Because of the patient’s young age, only 
chemotherapy according to the protocol for 
children below 3 years old was administered. 
Unfortunately, disease progression was ob-
served during chemotherapy and additionally 
ATRT was detected in the patient’s kidney. In 
the case of a second child histological diffi cul-
ties concerning tumour distinction between 
PNET, carcinoma plexus chorioidei and ATRT 
were noted. However, fi nal confi rmation of the 
ATRT diagnosis was achieved after specimen 
consultations and histochemical examinations 
(but not with immuno-histochemical data). 
So far, published treatment results have not 
been satisfactory. Long-term survivals are 
very rare. Many authors have observed that 
older age and female gender predicted better 
prognosis [1, 2, 4, 13, 15, 24, 25, 26, 27]. In our 
study group, only one child below 3 years old 
and 2 older children are alive. So far no stan-
dard methods for the most effective therapy 
have been developed, but a review of published 
materials showed that high-dose chemotherapy 
together with radiotherapy improved survival 
Pt Age years Sex Histopathology Location Treatment
Type of 
surgery Radiotherapy
PFS 
months
OS 
months Result
FF 4/12 M Medulloblas-
toma/ATRT
Inf S+CHT PR No 6 10 DOD
CD 4 F ATRT Sup S+CHT SR No 3 5 DOD
AG 2.5 F ATRT Inf S+CHT SR No 7 10 DOD
IM 2 F ATRT Sup S+CHT+RT PR CSI
35Gy+boost
55Gy
73 73 NED
EN 5 F ATRT Sup S+CHT+RT TR CSI
35Gy+boost
55Gy
72 72 NED 
second 
cancer
AG 11 M PNET/ca.plexus 
chorioidei/ATRT
Sup S+CHT+RT TR CSI
35Gy+boost
55Gy
7 9 DOD
WN 6 F ATRT/PNET Sup S+CHT+RT+CHT SR CSI
35Gy+boost
55Gy
13 25 DOD
MG 22 M ATRT Sup S+CHT+RT+CHT TR CSI
35Gy+boost
54Gy
28 28 NED
Legend:
Sup – supratentorial, Inf – infratentorial
S – surgery, CHT – chemotherapy, RT – radiotherapy
PR – partial resection, SR – subtotal resection, TR – total resection
PFS – progression-free survival
OS – overall survival
NED – no evidence of disease, DOD – dead of disease, LWD – living with disease 
Table 1. Results of treatment
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rate in ATRT [15]. We observed a similar ef-
fect in our study group. All living children 
have undergone high dose radiotherapy to the 
tumour bed and to the craniospinal axis as 
well. In St. Jude Hospital’s report, concerning 
31 children treated during 19 years, 2-year 
overall survival was 17%±8% and 89%±11% 
for the group of children below 3 years old 
and older children, respectively. There is no 
doubt that patient’s age and the presence of 
radiotherapy treatment prolonged survival in 
the described groups of patients. In the group 
of younger children disease progression dur-
ing chemotherapy was observed in 82% of pa-
tients and second-line chemotherapy failed. 
After rescue radiotherapy long-term remis-
sion was found in 2 children. There is no clear 
answer regarding the area of radiotherapy. 
However, in most cases relapses occur in the 
tumour bed [15]. This was also confi rmed in 
our material; only one patient had local pro-
gression together with dissemination before 
planned radiotherapy. 
Recently, CD133, a 5-transmembrane gly-
coprotein, was identifi ed as an important 
marker. Chou reported that the amount of CD 
133(+) in ATRT correlated positively with 
the degree of resistance to radiation therapy 
[28].
According to a multicentre register of 
ATRT where information about 42 chil-
dren was gathered, disease-free survival 
longer than 2 years was achieved in 24% of 
patients. All living patients underwent ag-
gressive treatment including total surgery, 
radiotherapy and/or intrathecal or high dose 
chemotherapy with stem cell graft [29]. Chen 
et al., in their report of 17 patients, found im-
portant prognostic factors using multivari-
ate analysis. Those factors included: clinical 
status of patients, radiotherapy dose, and 
time between surgery and radiation therapy. 
Eighty percent of patients suffered from dis-
seminated disease despite the fact that all of 
them received CSI. In the authors’ opinion, 
radiotherapy is a key method of ATRT treat-
ment. They recommend radiotherapy direct-
ly after surgical therapy [16]. Also, Mexican 
authors who observed 10 patients established 
that radiotherapy beside surgery comprised 
the major method of paediatric ATRT treat-
ment [30].
CONCLUSIONS
We conclude that radiotherapy with a higher 
dose (i.e. over 50 Gy) prolonged survival in 
ATRT and should be incorporated in all treat-
ment protocols for patients with this diagno-
sis. It is diffi cult to estimate the role of whole 
craniospinal axis radiotherapy because of dif-
ferent relapse character.
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